TransCode Therapeutics ( (RNAZ)) just unveiled an announcement. On December 19, 2025, TransCode Therapeutics appointed veteran life sciences executive Jack E. Stover to its board of directors, ...

CK Life Sciences International is set to merge its subsidiary Polynoma with Nasdaq-listed TransCode Therapeutics, in a move expected to boost the pipeline of anticancer drugs, according to the biotech ...

TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences Concurrent equity investment of $25 Million from CK Life Sciences into TransCode TransCode expands its ...

In a pair of deals, TransCode Therapeutics has bagged Polynoma and its phase 3 cancer vaccine, as well as a $25 million injection into its cash-strapped coffers—but in doing so, the company is trading ...

TransCode expands its microRNA-based pipeline with Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanoma Philippe Calais, PharmD, PhD, ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. TransCode Therapeutics ( (RNAZ)) has ...

BOSTON, May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA ...

Follows Safety Review Committee (SRC) approval based on safety data from patients in Cohorts 1 and 2 No significant safety or dose limiting toxicities reported in Cohorts 1 and 2 PK data from Cohorts ...

TransCode Therapeutics (NASDAQ:RNAZ) will execute its previously announced 1-for-33 reverse stock split on Dec. 4, 2024. The company’s common stock is expected to begin trading on a split-adjusted ...

TransCode Therapeutics shares are trading lower by 16% during Monday's session. The company announced a 1-for-33 reverse stock split. Unlock your all-in-one trading dashboard with real-time alerts, ...

BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced ...